학술논문
Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections.
Document Type
Article
Author
Chemaitelly, Hiam; Ayoub, Houssein H; AlMukdad, Sawsan; Faust, Jeremy S; Tang, Patrick; Coyle, Peter; Yassine, Hadi M; Thani, Asmaa A Al; Al-Khatib, Hebah A; Hasan, Mohammad R; Al-Kanaani, Zaina; Al-Kuwari, Einas; Jeremijenko, Andrew; Kaleeckal, Anvar H; Latif, Ali N; Shaik, Riyazuddin M; Abdul-Rahim, Hanan F; Nasrallah, Gheyath K; Al-Kuwari, Mohamed G; Butt, Adeel A
Source
Subject
*VACCINE effectiveness
*SARS-CoV-2 Omicron variant
*SARS-CoV-2
*
*
Language
ISSN
1195-1982
Abstract
Keywords: Hybrid immunity; natural infection; waning vaccine effectiveness; asymptomatic infection; Qatar; variant-containing COVID-19 vaccines EN Hybrid immunity natural infection waning vaccine effectiveness asymptomatic infection Qatar variant-containing COVID-19 vaccines 1 3 3 09/13/23 20230701 NES 230701 In October of 2022, Qatar introduced COVID-19 bivalent vaccination for persons >= 12 years using the 50- g mRNA-1273.214 vaccine combining SARS-CoV-2 ancestral and omicron BA.1 strains.[1] We estimated this vaccine's effectiveness against SARS-CoV-2 infection. Hybrid immunity, natural infection, waning vaccine effectiveness, asymptomatic infection, Qatar, variant-containing COVID-19 vaccines. [Extracted from the article]